免疫吸附治疗对自身免疫性疾病的疗效及安全性探讨  

The clinical efficacy and safety of immunoadsorbents on autoimmune diseases

作　　者：熊礼佳[1] 叶琨[1] 刘园园[1] 曾春[1] 刘芸芳[1] 彭小梅[1] 

机构地区：[1]广西壮族自治区人民医院肾内科,南宁530021

出　　处：《中国临床新医学》2017年第1期1-4,共4页CHINESE JOURNAL OF NEW CLINICAL MEDICINE

基　　金：广西科学研究与技术开发计划项目(编号:桂科攻1598012-11)

摘　　要：目的探讨免疫吸附治疗对自身免疫性疾病的疗效及安全性。方法选取2014-05~2015-07期间收治的自身免疫性疾病患者16例,其中系统性红斑狼疮(SLE)15例,抗肾小球基底膜(GBM)抗体患者1例,使用HA280或DNA230进行免疫吸附治疗,检测患者治疗前后ANA、ds-DNA、抗GBM抗体、Ig A、Ig G、Ig M、C3、C4及生化指标的变化。结果 9例SLE患者使用HA280免疫吸附后ANA、ds-DNA下降(P<0.05),6例SLE患者使用DNA230免疫吸附后ds-DNA明显下降(P<0.05),抗GBM病患者使用HA280连续免疫吸附治疗后抗GBM抗体转阴。所有患者治疗前后血常规及其他生化指标差异无统计学意义(P>0.05)。结论免疫吸附治疗可有效清除自身免疫性抗体,对自身免疫性疾病治疗有效,无明显不良反应,安全性好。Objective To observe the clinical effect and safety of immunoadsorbents on systemic lupus ery- thematosus（SLE）. Methods Sixteen patients including fifteen cases with SLE and one case with anti-glomerula basement membrane（GBM） disease were treated with HA280 or DNA230 immunoadsorbent. The autoimmune anti- bodies and other biochemical indexes of the patients were detected and analyzed before and after the treatment. Re- suits The titres of antinuclear antibody （ANA） and anti-double sranded antibody （ds-DNA） decreased in 9 cases with SLE after the treatment of HA280 （P 〈 0. 05）, and the titres of ds-DNA declined significantly in 6 cases with SLE ＂after the treatment of DNA230 （ P 〈 0. 05 ）. Anti-GBM antibody turned negative in 1 case with anti-glomerula basement membrane（ GBM ） disease. There were no significant differences in the other biochemical indexes in all the patients before and after the treatment. Conclusion Immunoasorbents HA280 and DNA230 are safe and effective to remove the autoimmune antibodies from the patients with autoimmune diseases.

关 键 词：免疫吸附 自身免疫性疾病 自身抗体 

分 类 号：R552[医药卫生—血液循环系统疾病]